Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.

Landray MJ, Reveal Collaborative Group; L. Bowman, F. Chen, E. Sammons, J.C. Hopewell, K. Wallendszus, W. Stevens, E. Valdes-Marquez, S. Wiviott, C.P. Cannon, E. Braunwald, R. Collins, M.J. Landray (Writing Committtee)..

Am Heart J. 2017 May;187:182-190. doi: 10.1016/j.ahj.2017.02.021. Epub 2017 Feb 21.

2.

Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis.

Di Bartolo BA, Schwarz N, Andrews J, Nicholls SJ.

Arch Med Sci. 2017 Feb 1;13(1):210-214. doi: 10.5114/aoms.2016.60941. Epub 2016 Jun 30.

3.

High-density lipoprotein: quantity or quality?

Tziomalos K.

J Thorac Dis. 2016 Nov;8(11):2975-2977. doi: 10.21037/jtd.2016.11.67. No abstract available.

4.

Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial.

Batuca JR, Amaral MC, Favas C, Paula FS, Ames PRJ, Papoila AL, Delgado Alves J.

Br J Clin Pharmacol. 2017 May;83(5):1002-1010. doi: 10.1111/bcp.13198. Epub 2017 Jan 18.

PMID:
27891663
5.

Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.

Girona J, Ibarretxe D, Plana N, Guaita-Esteruelas S, Amigo N, Heras M, Masana L.

Cardiovasc Diabetol. 2016 Aug 4;15(1):107. doi: 10.1186/s12933-016-0428-z.

6.

Unmet Needs in LDL-C Lowering: When Statins Won't Do!

Krähenbühl S, Pavik-Mezzour I, von Eckardstein A.

Drugs. 2016 Aug;76(12):1175-90. doi: 10.1007/s40265-016-0613-0. Review.

7.

Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes.

Tardif JC, Rhainds D, Brodeur M, Feroz Zada Y, Fouodjio R, Provost S, Boulé M, Alem S, Grégoire JC, L'Allier PL, Ibrahim R, Guertin MC, Mongrain I, Olsson AG, Schwartz GG, Rhéaume E, Dubé MP.

Circ Cardiovasc Genet. 2016 Aug;9(4):340-8. doi: 10.1161/CIRCGENETICS.116.001405. Epub 2016 Jul 14.

8.

HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?

Stefanutti C, Morozzi C.

Blood Transfus. 2016 Sep;14(5):408-12. doi: 10.2450/2016.0027-16. Epub 2016 Jun 29. No abstract available.

9.

The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications.

Feig JE, Feig JL, Dangas GD.

Coron Artery Dis. 2016 Nov;27(7):592-603. doi: 10.1097/MCA.0000000000000408. Review.

PMID:
27414247
10.

Selecting instruments for Mendelian randomization in the wake of genome-wide association studies.

Swerdlow DI, Kuchenbaecker KB, Shah S, Sofat R, Holmes MV, White J, Mindell JS, Kivimaki M, Brunner EJ, Whittaker JC, Casas JP, Hingorani AD.

Int J Epidemiol. 2016 Oct;45(5):1600-1616. Epub 2016 Jun 24.

11.

Newer antiatherosclerosis treatment strategies.

Aggarwal A, Singh S.

Heart Asia. 2011 Jan 1;3(1):26-30. doi: 10.1136/ha.2010.003129. eCollection 2011.

12.

Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects.

Small DS, Royalty J, Cannady EA, Hale C, Wang MD, Downs D, Suico JG.

Pharmacotherapy. 2016 Jul;36(7):749-56. doi: 10.1002/phar.1778. Epub 2016 Jul 8.

13.

Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.

Yeang C, Wilkinson MJ, Tsimikas S.

Curr Opin Cardiol. 2016 Jul;31(4):440-50. doi: 10.1097/HCO.0000000000000300.

PMID:
27205885
14.

Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS).

Afshar M, Pilote L, Dufresne L, Engert JC, Thanassoulis G.

J Am Heart Assoc. 2016 Apr 23;5(4). pii: e003012. doi: 10.1161/JAHA.115.003012.

15.

CETP Inhibition: Past Failures and Future Hopes.

Kosmas CE, DeJesus E, Rosario D, Vittorio TJ.

Clin Med Insights Cardiol. 2016 Mar 13;10:37-42. doi: 10.4137/CMC.S32667. eCollection 2016. Review.

16.

Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.

Reyes-Soffer G, Millar JS, Ngai C, Jumes P, Coromilas E, Asztalos B, Johnson-Levonas AO, Wagner JA, Donovan DS, Karmally W, Ramakrishnan R, Holleran S, Thomas T, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Liu Y, Lassman ME, Gutstein DE, Rader DJ, Ginsberg HN.

Arterioscler Thromb Vasc Biol. 2016 May;36(5):994-1002. doi: 10.1161/ATVBAHA.115.306680. Epub 2016 Mar 10.

17.

Integrated microRNA‑gene analysis of coronary artery disease based on miRNA and gene expression profiles.

Xu X, Li H.

Mol Med Rep. 2016 Apr;13(4):3063-73. doi: 10.3892/mmr.2016.4936. Epub 2016 Feb 23.

18.

Lipoprotein (a): Coming of Age at Last.

Witztum JL, Ginsberg HN.

J Lipid Res. 2016 Mar;57(3):336-9. doi: 10.1194/jlr.E066985. Epub 2016 Feb 2. Review. No abstract available.

19.

Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study.

Verbeek R, Boekholdt SM, Stoekenbroek RM, Hovingh GK, Witztum JL, Wareham NJ, Sandhu MS, Khaw KT, Tsimikas S.

J Lipid Res. 2016 Apr;57(4):697-705. doi: 10.1194/jlr.P066258. Epub 2016 Jan 31.

20.

Overcoming Challenges With Statin Therapy.

Spence JD, Dresser GK.

J Am Heart Assoc. 2016 Jan 27;5(1). pii: e002497. doi: 10.1161/JAHA.115.002497. Review. No abstract available.

Supplemental Content

Support Center